- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The Evolution of ALK+ NSCLC Care
Panelists discuss how they will explore optimizing care for patients with ALK-positive non-small cell lung cancer (ALK+ NSCLC) through treatment selection, sequencing strategies, and interpretation of emerging clinical data.
Panel Introduction
This summary is based on an AJMC Peer Exchange program titled “Advancing ALK+ NSCLC Care: Optimizing Treatment, Sequencing, and Long-Term Outcomes,” featuring the following experts:
- Ryan Haumschild, PharmD, MS, MBA, CPEL (Moderator) - vice president of Ambulatory Pharmacy at Emory Healthcare and Winship Cancer Institute of Emory University
- Elizabeth Castronovo, NP - advanced practice provider
- Martin Dietrich, MD, PhD - oncology specialist
- Mary Grizzard, MSN, FNP - family nurse practitioner
- Christine M. Lovly, MD, PhD, FASCO - oncology researcher/physician
Introduction and Treatment Landscape Evolution
- Dr Haumschild introduced the program focus on ALK+ NSCLC care optimization
- Dr Lovly posed a question regarding how the treatment landscape has evolved in recent years
- Panelists established the foundation for discussing advances in ALK-targeted therapies
Program Overview
The panelists explore strategies for optimizing care of patients with ALK-positive non–small cell lung cancer through evidence-based treatment selection, sequencing approaches, and interpretation of emerging clinical data to improve long-term outcomes.
Addressing KRAS Resistance, RAS(ON) Therapies Find Limelight at AACR
May 5th 2025KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, as highlighted at the 2025 meeting of the American Association for Cancer Research (AACR).
Read More
Expanding Resources, Clinical Knowledge to Enhance AYA NHL Care: Andrew Evens, DO
May 2nd 2025To better treat adolescent and young adult (AYA) patients with various subtypes of Hodgkin and non-Hodgkin lymphomas (NHL), Andrew Evens, DO, speaks to the importance of primary care, screening access, and research.
Read More
